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Abstract 
Background: 
Remifentanil is associated with subjective dysphagia and an objective increase in aspiration risk. 
Studies of opioid effects have shown decreased lower esophageal sphincter relaxation. We assessed 
bolus transit through the esophagus and esophagogastric junction (EGJ) during remifentanil 
administration using objective pressure flow analysis. 
Methods: 
Data from eleven healthy young participants (23±3 yrs., 7M) were assessed for bolus flow through 
the esophagus and EGJ using high-resolution impedance manometry (Manoscan™, Sierra Scientific 
Instruments, Inc., LES Angeles, CA) with 36 pressure and 18 impedance segments. Data was analyzed 
for esophageal pressure topography and pressure flow analysis using custom Matlab analyses 
(Mathworks, Natick, US). Paired t-tests were performed with a P-value of < 0.05 regarded as 
significant. 
Key Results: 
Duration of bolus flow through (remifentanil/R 3.0±0.3 vs baseline/B 5.0±0.4 sec; P < 0.001) and 
presence at the EGJ (R 5.1±0.5 vs. B 7.1±0.5 sec; P = 0.001) both decreased during remifentanil 
administration. Distal latency (R 5.2±0.4 vs B 7.5±0.2 sec; P < 0.001) and distal esophageal 
distention-contraction latency (R 3.5±0.1 vs. B 4.7±0.2 sec; P < 0.001) were both reduced. Intrabolus 
pressures were increased in both the proximal (R 5.3±0.9 vs. B 2.6±1.3mmHg; P = 0.01) and distal 
esophagus (R 8.6±1.7 vs B 3.1±0.8mmHg; P = 0.001). There was no evidence of increased esophageal 
bolus residue. 
Conclusions & Inferences: 
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Remifentanil-induced effects which were different for proximal and distal esophagus, with a reduced 
time for trans-sphincteric bolus flow at the EGJ, suggestive of central and peripheral μ-opioid 
agonism. There were no functional consequences in healthy subjects.  
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 Key points: 
 Mu-opioid receptor agonism induces the symptom dysphagia, as well as changes in 
esophageal motility and lower esophageal sphincter relaxation. We assessed the functional 
effects of such changes. 
 MOR agonism has differential effects in the proximal and distal esophagus, however trans-
sphincteric bolus flow is maintained through increased intrabolus pressure. 
 Remifentanil leads to reduced proximal skeletal muscle contractility and a loss of inhibition 
in the distal (smooth muscle) esophagus, with resulting shortened distal latency, increased 
contractile vigor and numerically increased IRP. 
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Introduction  
Remifentanil is an ultra-short acting mu opioid receptor (MOR) agonist, used during anaesthesia for 
its centrally depressing and anti-nociceptive effects. Many individuals, including healthy volunteers, 
complain of dysphagia during administration of remifentanil1,2. Recent descriptions of the effects of 
remifentanil and other MOR agonists on swallowing function have revealed attenuated 
oropharyngeal3,4 and laryngeal5 (sensory function, increased pulmonary aspiration2, decreased distal 
esophageal latency6,7 and decreased esophagogastric junction (EGJ) relaxation6-11. Esophageal 
pressure topography (EPT) revealed a shortened distal latency and increased distal intrabolus 
pressure during remifentanil administration7. The integrated relaxation pressure in 4 seconds (IRP4), 
a measure of EGJ relaxation, increased but remained well within physiological limits. Patients on 
chronic opioids frequently have evidence of EGJ obstruction and likely related distal esophageal 
hypercontractility6. The mechanisms of the observed esophageal changes and the origin of the 
sensation of dysphagia are incompletely understood.  
The use of computer-based analyses of high-resolution impedance manometry recordings enables 
us to relate pressure-flow phenomena to their functional consequences, including the completeness 
of impedance-based bolus passage and bolus-based esophageal distention and related pressures12. 
Separate evaluation can be undertaken of the proximal and distal esophagus, as well as the EGJ with 
the intention to relate pressure-flow phenomena to physiology, pathophysiology, and symptoms12,13. 
Esophageal pressure flow analysis has not been performed during administration of remifentanil and 
offers the opportunity to enhance our understanding of changes in esophageal physiology induced 
by opioids. 
Bolus-flow phenomena are important in determining successful bolus passage through the hollow 
organs of the gastrointestinal tract such as the tubular esophagus. This is of particular interest as the 
human esophagus consists of proximal striated and distal smooth muscle, with potentially different 
effects in relation to such physiological events as bolus-based distention. Our group has previously 
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described the concept of the ‘neuromechanical loop’ in which bolus distention causes orad 
contraction and aboral relaxation of circular muscle with the subsequent movement of content then 
generating the new mechanical stimulus that activates intramuscular tension receptors reinitiating 
the sequence14,15. Page and colleagues described attenuated responses in mucosal and tension 
receptors following MOR agonism in the ferret esophagus, meaning a greater stimulus is needed to 
invoke the same neuro-mechanical response16. It can thus be hypothesised that the increased 
intrabolus pressure observed during remifentanil exposure represents retained bolus due to 
decreased EGJ relaxation7. In this study we sought to further characterise the effect of MOR on 
esophageal segment physiology using state of the art methods. We therefore conducted novel 
pressure-impedance analyses on manometric recordings from healthy volunteers before and during 
remifentanil administration. The aim of this study was to determine how mechanisms of 
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Methods and Materials 
Subjects 
Data from eleven healthy young participants (mean age 23±3 yrs, 7 male), collected at the 
Department of Anaesthesiology, University Hospital in Örebro, Sweden, were analysed. All 
participants were previously enrolled in a double-blind, randomized, placebo-controlled; cross-over 
study of opioid drugs on pharyngeal swallowing3 and all gave informed consent. The protocol of this 
study was reviewed and approved by the Central Ethics Review Board in Uppsala, Sweden. None of 
the participants smoked, reported any current or past symptoms of dysphagia or upper 
gastrointestinal diseases, or took any medications that could affect pharyngeal or esophageal 
function. Exclusion criteria for this study included potential pregnancy, current breastfeeding, or 
previous participation in a medical study.  
 
Intervention 
Intravenous target controlled infusion was used to administer remifentanil with an effect-site 
concentration of 3 ng/ml (Minto Model, Alaris PK syringe pump, Alaris Medical Nordic AB, 
Sollentuna, Sweden). The infusion pump uses a 3-compartment model described by Minto17,18 
(variates are lean body mass and age) to calculate dose administration. The system delivers a brief, 
rapid infusion to reach the targeted effect size concentration without overshoot, followed by a 
series of decreasing infusion rates to maintain the targeted concentration.  
 
High-Resolution Impedance Manometry 
Manometry and impedance data were recorded using a 4.2mm diameter catheter housing 36 
circumferential pressure sensors that were spaced 1 cm apart and 18 x 2 cm long impedance 
segments (Manoscan™, Sierra Scientific Instruments, Inc., LES Angeles, CA). Catheter calibration was 
performed in accordance with manufacturer specifications, before the catheter was placed 
transnasally so that sensors straddled the entire esophagus and esophagogastric junction (EGJ). 
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Participants rested for a period of 5 minutes to accommodate to the catheter in situ. Participants 
then ingested ten 10ml saline boluses on command, once every 20 seconds before and 15 min and 
30 min following commencement of remifentanil administration. In the present study, we compare 
data recorded at baseline to those recorded at 30 min following the commencement of remifentanil 
infusion as the steady state plasma concentration is rapidly achieved by target controlled infusion 
systems and we previously demonstrated that the pharmacodynamic effects at 15 min and 30 min 
did not differ3 . 
 
EGJ Metrics  
Bolus flow through the EGJ was determined as described by Lin et al.19. In brief, the method consists 
of creating a virtual e-sleeve at the EGJ to simultaneously measure pressure and impedance data in a 
custom Matlab program (Mathworks, Natick, MA). The pressure and impedance data were used to 
determine the direction of flow and a flow gradient, by using the proximal pressure sensor and a 
referenced gastric pressure. Lin et al.19 determined criteria for bolus flow (bolus presence in the EGJ 
and flow permissive pressures) through comparison of measured data with radiologically 
determined EGJ bolus flow. Bolus flow was determined to be halted when the crural diaphragm 
pressures were above that of the pressure just proximal to the level of the sphincter within the zone 
of the bolus presence time. Bolus presence above the LES is expressed here as bolus presence time 
(BPT). Distention impedance and pressure were determined for the EGJ in the same way as that for 
the esophagus described below. The EGJ nadir pressure was also measured as a discreet value. 
Pressure Flow Analysis  
Swallows were analysed using purpose designed software (based in MATLAB version 8.5.0.197613 - 
R2015a; The MathWorks Inc, Natick, US), which automatically interpolated (Piecewise Cubic Hermite 
Interpolating Polynomial) the pressure and impedance data to increase the dataset to a 1mm spatial 
resolution.   
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Five space-time landmarks were determined on the plot as follows (see also Figure 1):  
1. Swallow onset determined by the onset of upper esophageal sphincter (UOS) relaxation. 
2. The temperospacial position of the peak esophageal pressure at the orad margin of the 
proximal esophagus.  
3. Position of mid-point of the transition zone between striated and smooth muscle 
esophagus, defined as the lowest pressure between proximal and distal esophageal 
pressure sequences or the distal margin of the proximal esophageal contraction in the 
case of large peristaltic breaks  
4. The proximal margin of the LES high-pressure zone post-swallow 
5. The distal margin position of the LES high-pressure zone, defined by lowest position of 
the distal edge of the high-pressure zone pre and/or post swallow.  
These landmarks guided the calculation of values for a range of esophageal and EGJ variables. 
Esophageal Pressure Flow Variables 
Swallow function variables during PFA were determined for the whole esophagus and esophagus 
proximal to, but excluding the transition zone (proximal esophagus) and esophagus from the 
(transition zone to the proximal margin of the LES high-pressure zone (distal esophagus). As it has 
been determined that nadir impedance correlates with maximal luminal cross-sectional area as 
measured radiologically20,21 or via ultrasound22, the following PFA variables were derived: (i) 
Distention impedance, determined as the mean nadir impedance for the respective esophageal 
segment. (ii) Distention pressure, an intrabolus pressure variable, measured at the point of maximal 
luminal distention and averaged for the esophageal segment. (iii) Peak pressure, the mean value of 
maximum contractile pressures along the length of the esophageal segment. (iv) The time between 
peak distention (nadir impedance) and peak pressure, termed the distention contraction latency 
(DCL). (v) The mean distention contraction latency, as the time between nadir impedance and peak 
pressure DCL, determined per esophageal segment. (vi) The total length of breaks in the 20mmHg 
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isocontour, measured as 20mm isocontour defects (ICD). (vii) Impedance ratio, determined for the 
complete distal esophagus as the mean value of the ratio of nadir impedance to the impedance at 
peak pressure. A higher ratio implies relatively more bolus retention as the drop in impedance is 
determined by the presence of bolus.  
Esophageal Pressure Topography 
Esophageal Pressure Topography was determined as by Chicago Classification Criteria23. Swallow 
onset was defined as the onset of relaxation in the upper esophageal sphincter (UOS) high-pressure 
zone. The integrated relaxation pressure in 4 seconds (IRP4) was determined as the lowest 
contiguous or non-contiguous pressure in the lower esophageal sphincter (LES) high-pressure zone 
in the ten seconds following swallow onset. IRP4 is referenced to intragastric pressure. Contraction 
deceleration point (CDP) was determined as the inflection in peristaltic velocity within the distal 
esophagus 2-3 cm from the EGJ. This inflexion is indicative of the formation of the phrenic ampulla 
associated with distal esophageal bolus clearance. The time from swallow onset to the CDP was 
termed the distal latency (DL), measured in seconds. Peristaltic velocity was determined by drawing 
a line parallel to the 30mmHg isocontour starting at the CDP and extending proximally.  
 
Statistical analysis 
Bonferroni-adjusted paired t-tests were used to compare outcome variables measured before and 
during exposure to remifentanil. These are presented here as mean ± standard error (t-statistic) with 
a p-value <0.05 indicating statistical significance. 
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Results 
The total cumulative dose of remifentanil administered in our volunteers ranged from 346 to 487 µg. 
Two of the subjects reported a subjective sensation of dysphagia during the infusion, while some 
other subjects reported nausea. Most of the subjects described feeling sedated. All the side-effects 
rapidly disappeared on stopping the infusion.  
An overview of esophageal pressure topography and impedance of five consecutive swallows at 
baseline and at 30 minutes during remifentanil infusion are depicted as Figure 2.  
The main effects are demonstrated in Figures 3-5 with mean values shown in Tables 1 and 2.  
 
Bolus flow through the EGJ 
Effects on bolus flow as measured through bolus flow time and bolus presence time are pictured in 
Figures 3, 4 and Table 1. Both BFT and BPT were markedly reduced during administration of 
Remifentanil (Table 1). 
 
Pressure Flow Analysis 
Effects of Remifentanil on pressure flow analysis are shown in Table 1. Peristalsis remained intact 
and of an equivalent vigor in the distal esophagus. There were reduced peak pressures in the 
proximal (striated) esophagus. There was evidence of increased intrabolus distension pressures 
throughout the esophagus. Additionally, IBP slope increased significantly in the distal esophagus only 
from 1.1± 0.6 mmHg/s pre to 3.9±0.9mmHg/s during remifentanil exposure (P = 0.03). Esophageal 
luminal cross-sectional area, inferred by distension impedance, remained unchanged throughout the 
esophagus. Distention-contraction-latency time (DCL) was significantly shorter during remifentanil 
exposure in the distal esophagus only (Figure 5B&C). 
 
Esophageal Pressure Topography 
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Effects of Remifentanil on EPT metrics are shown in Table 2. No subjects fulfilled Chicago 
classification diagnosis for motor abnormalities prior to commencing the remifentanil infusion.  
The most marked effect of Remifentanil exposure was a reduced distal latency (Table 2; Figure 5A). 
In addition, there was a strong trend approaching significance for increased peristaltic velocity in the 
smooth muscle esophagus, likely associated with the shortening of distal latency24. There were no 
statistically significant differences in peristaltic vigor as measured through DCI. EGJ relaxation 
pressures as measured by IRP4 were not significantly different during remifentanil exposure overall, 
even though the IRP4 was increased numerically in 6 of the subjects. 
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Discussion 
In this study we evaluated the pharmacodynamic effects of the mu opioid receptor (MOR) agonist 
remifentanil on esophageal bolus transport and emptying mechanisms. Remifentanil induced a 
pattern of changes in esophageal function with the net effect of increasing bolus flow resistance 
during compartmentalised transport and esophageal emptying. The main effects of remifentanil 
were on esophageal body distension pressures and motility with some contrasting effects localised 
in the proximal and distal regions of the esophagus, which have differing underlying physiology. In 
the proximal striated muscle esophagus, remifentanil i) increased distension pressures and ii) 
weakened contractility. In the distal smooth muscle esophagus, remifentanil i) reduced swallow-
contraction latency, ii) reduced distension-contraction latency and iii) increased distension 
pressures, but (iv) did not weaken contractility or impair bolus clearance. In the EGJ, remifentanil (i) 
did not significantly alter relaxation residual pressures, however (ii) EGJ bolus flow time was shorter 
in concert with (iii) a shorter period of bolus presence within the distal esophagus. Altogether, these 
findings suggest that remifentanil exposure primarily alters timing of smooth muscle peristalsis and 
duration of EGJ opening.  
Remifentanil effects on proximal esophageal motility 
The central nervous system, via brainstem based central pattern generators of swallowing, initiates 
and controls proximal striated muscle peristalsis via sequential activation of motor neurone pools 
within the nucleus ambiguus25. Central sensory relay occurs in the nucleus tractus solitarius (NTS)26, 
and motor outputs are modulated in response to sensory input for different bolus 
characteristics27,28. In our study, remifentanil exposure reduced proximal esophageal contractility, 
suggesting either central effects leading to attenuated motor neurone activation or, alternatively, 
peripheral effects at the striated neuromuscular junction. Central modulation may occur at the level 
of the NTS as it has been shown to contain MOR29,30. However, one might expect that besides 
reduced contractile vigour, modulation of central pattern generator activity in the NTS would also 
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result in altered contractile sequence, which was not the case in our study. Similarly, Storr and 
colleagues31 demonstrated that exposure to the MOR endogenous ligands Endomorphin-1 and -2 
induced a reduction in the contractile response of rat striated muscle esophagus to electrical field 
stimulation (EFS) in vitro. In contrast to the effects on amplitude, the timing of the proximal 
contractile sequence was unaffected by remifentanil. This suggests that, like in the pharyngeal 
contraction sequence3,4, the centrally determined neural timing sequence governing velocity of 
propagation of proximal esophageal contraction remains unchanged by opioids and that the 
observed effects are more likely due to peripheral MOR effects.  
 
Remifentanil effects on distal esophageal motility 
In contrast to the lack of effect on the proximal peristalsis pattern, remifentanil exposure markedly 
altered the timing of distal peristalsis below the transition zone. Specifically, remifentanil caused 
distal peristalsis to become more rapidly propagated, hence reaching the EGJ earlier (shorter 
latency), whilst at the same time the distal contractile amplitude was unchanged. As distal smooth 
peristalsis is controlled via activation of the enteric nervous system24,32,33, we propose that our 
findings are consistent with peripheral MOR agonism causing an excitatory-inhibitory ‘imbalance’ 
due to a selective reduction of nitric oxide (NO) release by inhibitory neurons. Such effects would be 
in keeping with the clinical observation of an increased incidence of spastic motor disorders of the 
distal esophagus in chronic opioid users, reported by Ratuapli et al.7  
Normally propagated primary peristalsis of the smooth muscle esophagus results from vagally 
mediated activation of nitrergic inhibitory neurons, followed by activation of cholinergic excitatory 
neurones. Along the esophageal body, the relative density of inhibitory innervation increases distally 
and so does the latency period from swallow to muscle contraction, producing the orderly and 
distally propagating peristaltic behaviour that is typically seen in healthy subjects24. Via its effects on 
the CNS, remifentanil may in theory attenuate the vagal preganglionic nerve activation with the 
knock-on effect of altered post-ganglionic neurotransmitter release. However, as this effect would 
C o c k  | 17 
 
impact equally on both inhibitory and excitatory pathways, the overall timing of the distal peristalsis 
would not be expected to change, but perhaps rather its overall contractile amplitude be 
attenuated. We therefore propose that the main effects of MOR agonism are most likely via 
peripheral mechanisms, in particular reduced peripheral NO release by antagonising NO-synthase 
production33. Reduced peripheral NO release best explains our latency findings as they are akin to 
the effects of the NO synthase inhibitor nitro-L-arginine methyl ester hydrochloride (L-NAME) which 
induces a similar rapid peristaltic sequence pattern in healthy volunteers34. An alternative peripheral 
mechanism may be remifentanil-induced disruption of sensory mechano-receptor mediated 
peripheral circuits that modulate peristalsis in relation to luminal stimuli, most notably bolus-based 
distension35. Whilst impairment of sensory modulation of peristalsis may in part explain the elevated 
distension pressures seen, it would also attenuate both inhibitory and excitatory pathways and 
therefore seems an unlikely mechanism governing the imbalance suggested by shorter distention 
contraction latency. This is further supported by the observation that in the lower gut, opioids 
abolish, rather than modify, propagation of distension-induced peristalsis by completely interrupting 
neuroneuronal and neuroeffector transmission35,36.  
Remifentanil effects on lower esophageal sphincter and EGJ 
Using manometry with circumferential or unidirectional pressure sensing, we can only assess the 
sum effect of MOR agonism on LES tone and relaxation, which is complete relaxation of a shorter 
duration. We lack the resolution to appreciate the radial asymmetry or assess striated and smooth 
muscle components separately. Importantly bolus transit through the LES is not affected by 
remifentanil (Fig 1 & 2), and the rapid propagation of the distal contraction continues to the LES and 
leads to increased intrabolus pressure above the LES. The bolus traverses the sphincter more rapidly 
due to the greater pressure differential between the distal esophagus and intragastric pressure. 
There are several potential explanations for the increased IRP4 seen in the majority of subjects in 
our study and previously observed during MOR agonist administration7. Firstly, in our study 
sphincter relaxation is of a shorter duration than the four seconds included in calculating IRP. 
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Secondly increased intrabolus pressures will also increase IRP. Lastly, it is possible that remifentanil 
may have differential effects on striated and smooth muscle and/or the different smooth muscle 
components of the LES, or differential central and peripheral neural inhibition.  
Nitric oxide is the main neural inhibitor involved in swallow-induced LES relaxation37-41. The LES is 
complex and consists of both external striated (diaphragmatic crus) and internal smooth muscle 
components. Furthermore, the smooth muscle consists of three different components with differing 
responses to neurotransmission from locally projecting myenteric fibers. Clasp and sling smooth 
muscle fibers react differently to neural excitation and inhibition42,43, while the distal esophageal 
circular muscle forms a third separate smooth muscle component of the LES, similar in response to 
sling fibres43. Both clasp and sling fibers relax in response to NO. However, this relaxation is much 
more pronounced in the clasp fibers40,41, so that modulating effects of remifentanil attenuating NO 
release are likely to affect this component of the LES to a greater degree. Technology with the ability 
to assess LES pressure symmetry or striated and smooth muscle components separately may be able 
to elucidate the effects of remifentanil or other MOR agonists on the LES to a greater extent. 
Limitations  
We acknowledge that this study has some limitations. For example, the additional use of opioid 
receptor antagonism, such as naloxone, would have added to the findings in our study. Of note, 
previous studies have failed to demonstrate a reversal of the effects of remifentanil by either 
naloxone or methylnatrexone1,7, however a supratherapeutic dose of naloxone may be needed to 
reverse the effects of remifentanil44. When considering remifentanil as a model for mu-opioid 
agonism, we acknowledge that the pharmacokinetics of remifentanil is markedly different from that 
of longer acting mu-opioids and thus any inference that longer acting mu-opioid agonists will have 
similar effects are only an assumption. Furthermore, we did not study the pharmacodynamics of 
remifentanil in our study. Whilst we did not directly correlate impedance based bolus flow in the 
esophagus or at the EGJ with simultaneous radiology, we note previous studies46 validating nadir 
impedance as a marker of bolus distension and the bolus flow time to quantify the period of 
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esophageal emptying19,47. Swallowing maneuvers, including multiple rapid swallows, were not 
performed, but would have had utility in determining the level at which (whether centrally or 
peripherally) swallowing inhibition, leading to a shortened distal latency, originates33.  Finally, we did 
not assess bolus volume effects or compare different bolus viscosities which may reveal altered 
sensory modulation of swallow features. 
 
Conclusion   
In summary, we reported on remifentanil induced changes in the proximal and distal esophagus, as 
well as at the EGJ. Proximally, there was a reduction in esophageal contractility and increased 
intrabolus pressures, a known correlate of bolus perception13. Distal changes in distention pressure 
and latency were in keeping with a reduction of descending deglutitive inhibition and, at the EGJ, 
there was a reduced duration of trans-sphincteric bolus flow. Overall, although the changes in 
esophageal motility during liquid swallows did not generate symptoms of dysphagia, these observed 
changes may become more relevant when swallowing boluses of solid consistencies, when 
undertaking provocative challenges such as multiple rapid swallows, and/or if evaluated in 
individuals with minor esophageal motor disorders. This study has important implications for the 
interpretation of upper gastrointestinal symptoms, particularly considering a recent trend towards 
large numbers of opioid prescriptions47.  
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TABLE 1. Pressure flow analysis of esophagogastric junction (EGJ) and Esophageal Metrics 
prior to (Baseline) and 30 minutes during administration of Remifentanil (at 30 minutes). 
 
AIMplot Derived Metrics Baseline Remifentanil t-statistic p-value 
Whole Esophagus 
20mmHg ICD cm 
Impedance Ratio 
 
2.6 ± 1.0 
0.22 ± 0.03 
 
2.7 ± 1.0 








Distension Impedance Ohms 
Distension Pressure mmHg 
 Peak Pressure mmHg 
Distension-Contraction Latency sec 
 
237 ± 17 
2.6 ± 1.3 
65 ± 4 
2.2 ± 0.2 
 
248 ± 12 
5.3 ± 0.9 
45 ± 6 












Distension Impedance Ohms 
Distension Pressure mmHg 
 Peak Pressure mmHg 
Distension-Contraction Latency sec 
 
197 ± 13 
3.1 ± 0.8 
59 ± 8 
4.7 ±0.2 
 
196 ± 11 
8.6 ± 1.7 
69 ±11 












Nadir Pressure mmHg 
Distension Impedance Ohms 
Distension Pressure mmHg 
Bolus Presence Time sec 
Bolus Flow Time sec 
 
2.4 ± 0.9 
157 ± 12 
-0.1 ± 1.5  
7.5 ± 0.5 



















ICD = isobaric contour defect, cm = centimetre, mmHg = millimetre of mercury, sec = seconds. 
TABLE 2. Esophageal Pressure Topography Metrics prior to (Baseline) and 30 minutes during 
administration of Remifentanil (Remifentanil). 
 
Manoscan OPT Metrics Baseline Remifentanil t-statistic p-value 
 
Contractile Front Velocity mmHg/sec 
Distal Latency sec 
Distal Contractile Integral mmHg.s.cm 
Integrated Relaxation Pressure mmHg 
 
3.8 ± 0.4 
7.5 ± 0.2 
1104 ± 248 
11.6 ± 2.4 
 
5.2 ± 0.4 
5.2 ± 0.4 
1533 ± 480 











mmHg/sec = millimetre of mercury per second, sec = seconds, mmHg.s.cm = millimetre of mercury per 
second per centimetre, mmHg = millimetre mercury 
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FIGURE LEGENDS 
FIGURE 1. Esophageal pressure topography (A), esophageal contour plot (B) and peak distention and contraction used during 
pressure flow analysis (C). Five user defined landmarks are used for analysis, namely (1) swallow onset, (2) orad onset of peak 
pressure wave – both time and space, (3) midpoint of transition zone, (4) proximal margin of the EGJ high-pressure zone and 
(5) distal margin of the EGJ high-pressure zone. Inter contour defect (ICD) and distention contraction latencies (DCL) are 
pictured. During pressure flow analysis mean values are determined for the proximal (P) and distal (D) esophagus. Flow 
through the EGJ is analysed separately.  
 
FIGURE 2. Example esophageal body pressure and impedance topography plots for consecutive swallows in a healthy subject 
prior to (A) and during (B) remifentanil administration.  
 
FIGURE 3. Distal latency (A) and distention contraction latency for the proximal (B) and distal (C) esophagus during 
remifentanil. 
 
FIGURE 4. EGJ bolus flow in healthy volunteers following remifentanil. Reduced bolus presence and flow times are observed 




FIGURE 5. Overlay of esophageal body topography and distention timing. From these data it is apparent that timing and 
velocity remains constant in the proximal esophagus with reduced distention contraction latency and increased velocity in the 
distal esophagus during remifentanil.  
 
 
